エピジェネティック解析が白血病の新たなサブタイプを解明(Epigenetic mapping provides deeper insight into leukaemia)

ad

2026-07-09 カロリンスカ研究所(KI)

カロリンスカ研究所と京都大学の国際研究チームは、急性骨髄性白血病(AML)1,563例を対象とした大規模エピゲノム解析により、DNA配列の変化ではなく遺伝子発現を制御する「エピゲノム」の違いが、白血病の多様性を規定する重要な要因であることを明らかにした。研究では、クロマチンの開放状態(DNAアクセシビリティ)を解析し、AMLを16種類の新たな分子サブグループに分類した。さらに、遺伝子発現、DNAメチル化、単一細胞解析などを統合した結果、各グループは異なる細胞分化状態や病態進行、患者予後、薬剤感受性を示すことが判明し、一部では従来の遺伝子変異に基づく分類よりも予後との関連が強かった。また、250種類の薬剤に対する反応性にもサブグループ間で差が認められ、エピゲノム情報を活用した個別化医療や治療法選択への応用が期待される。一方で、この分類は既存の遺伝学的診断を置き換えるものではなく、それを補完する新たな診断・治療指標として、今後の臨床検証が必要とされる。

<関連情報>

急性骨髄性白血病のクロマチン構造とエピジェネティックな異質性 Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia

Yotaro Ochi,Markus Liew-Littorin,Yasuhito Nannya,Sofia Bengtzen,Benedicte Piauger,Stefan Deneberg,Martin Jädersten,Vladimir Lazarevic,Jörg Cammenga,Anna Robelius,Lovisa Wennström,Emma Ölander,Senji Kasahara,Nobuhiro Hiramoto,Nobuhiro Kanemura,Nobuo Sezaki,Maki Sakurada,Makoto Iwasaki,Junya Kanda,Yasunori Ueda,Satoshi Yoshihara,Tom Erkers,Nona Struyf,Yu Watanabe,… Seishi Ogawa
Nature  Published:08 July 2026
DOI:https://doi.org/10.1038/s41586-026-10703-4

エピジェネティック解析が白血病の新たなサブタイプを解明(Epigenetic mapping provides deeper insight into leukaemia)

Abstract

Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1,2,3,4,5,6,7,8; however, the role of epigenetic alterations in these respects has been investigated less extensively. Here we use ATAC-seq (assay for transposase-accessible chromatin with sequencing) in a cohort of 1,563 individuals with a recent diagnosis of AML (the ‘eCHROMA’ cohort) to show that AML can be classified into 16 subgroups on the basis of chromatin accessibility profiles. Multiomics analyses of gene mutations, the transcriptome, DNA methylation and histone marks show that these ATAC subgroups exhibit distinct driver mutations, differentiation states, gene expression, DNA methylation and super-enhancer profiles, and are also associated with clinical outcomes. These findings were validated in independent cohorts. Single-cell ATAC sequencing reveals that all leukaemic cells in each subgroup share a common chromatin accessibility profile, which suggests that subgroup-specific epigenomic fingerprints underlie the ATAC-based classification. Mechanistically, the subgroups have distinct gene-regulatory networks that are driven by the activities of key transcription factors in haematopoiesis, and in which subgroup-specific super-enhancers have a pivotal role. Multiomics single-cell analysis further reveals deregulated trajectories of differentiation coupled with chromatin accessibility and gene expression. Notably, ATAC subgroups have an independent prognostic effect, compared with genomic classification, and are associated with particular drug sensitivities. In summary, ATAC-based chromatin profiling, combined with multiomics data, provides insights into AML pathogenesis beyond genomics and constitutes a valuable resource for AML research.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました